Twist Bioscience (TWST) AI Stock Analysis

• Market Cap: $1.96B
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.12
• Revenue Growth: 20.32%
• EPS Growth: 63.81%
• Country: US
• Employees: 923
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.45
• Shares Outstanding: 61,148,026
• 10 Day Avg. Volume: 1,263,242
• 30 Day Avg. Volume: 1,623,284
• PEG Ratio: 0.34
• Price to Book (P/B): 3.56
• Price to Sales (P/S): 4.47
• P/FCF Ratio: -22.25
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 4.10
• Enterprise Value/Gross Profit: 8.08
• Enterprise Value/Ebitda: -29.57
• 1Y Price Target: $38.00
• Price Target Upside: 46.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $28.00 ▲(7.69% Upside)

Twist Bioscience's overall stock score is primarily impacted by its financial performance and technical analysis. Despite revenue growth and margin improvements, significant profitability and cash flow challenges persist. The technical indicators suggest a bearish trend, and the valuation remains unattractive due to negative earnings. While the earnings call highlighted strong growth and future potential, the immediate financial and technical challenges weigh heavily on the score.

Twist Bioscience Business Overview & Revenue Model

Company Description

Twist Bioscience is a biotechnology company that specializes in synthetic DNA production and gene synthesis. Founded in 2013 and headquartered in San Francisco, California, the company operates primarily in the life sciences sector and serves various industries including pharmaceuticals, agriculture, and industrial biotechnology. Twist Bioscience's core products include synthetic genes, gene fragments, and other DNA-based products, which are utilized in research, development, and manufacturing processes.

How the Company Makes Money

Twist Bioscience generates revenue primarily through the sale of synthetic DNA products, which are utilized by customers in genetic research, drug development, and various industrial applications. The company's revenue model is based on a combination of direct product sales, service contracts, and partnerships with pharmaceutical and biotechnology companies. Key revenue streams include sales of custom gene synthesis, oligonucleotides, and other DNA-related products. Additionally, Twist has formed strategic collaborations with leading organizations in the life sciences sector to expand its market reach and enhance its product offerings, which further contributes to its earnings. The company's innovative approach and scalable technology platform enable it to meet the growing demand for synthetic biology solutions, positioning it for continued growth in the biotechnology market.

Twist Bioscience Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Twist Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Positive. The current price of 26 is below the 20-day moving average (MA) of 30.70, below the 50-day MA of 30.92, and below the 200-day MA of 32.79, indicating a neutral trend. The MACD of 0.45 indicates Negative momentum. The RSI at 55.18 is Neutral, neither overbought nor oversold. The STOCH value of 43.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TWST.

Twist Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
CDNA	77 Outperform	$1.00B	16.09	24.11%	―	14.46%	―
GRAL	70 Outperform	$3.35B	-7.61	-16.83%	―	20.53%	82.91%
FLGT	57 Neutral	$850.09M	-20.02	-3.80%	―	13.60%	74.64%
NEO	55 Neutral	$1.50B	-13.16	-12.99%	―	10.10%	-44.29%
MYGN	49 Neutral	$647.84M	-1.55	-72.52%	―	0.21%	-233.51%
TWST	43 Neutral	$1.96B	-24.38	-16.43%	―	20.32%	63.81%

Twist Bioscience Corporate Events

Twist Bioscience Faces Scaling Challenges: Potential Impact on Future Demand and Financial Health

Twist Bioscience faces a significant risk in its ability to scale manufacturing capacity to meet future demand, which could adversely impact its business operations. Although the current capacity meets existing demand, the unpredictability of future demand poses a challenge, potentially leading to excess inventory and financial losses. The complexity of their technology and production processes may result in unforeseen difficulties, diverting resources from other product offerings. Failure to expand manufacturing capacity efficiently could materially harm their business, financial condition, and operational results.

Twist Bioscience Reports Record Revenue and Growth

Twist Bioscience’s recent earnings call conveyed a positive sentiment, highlighting strong financial performance with record revenues and significant margin improvements. The company’s growth in SynBio, Biopharma, and NGS segments contributed to this success. Despite challenges such as the transition of a major customer and moderate growth guidance for fiscal 2026, Twist Bioscience remains optimistic about future growth driven by AI-enabled discovery and new product introductions.

Twist Bioscience Achieves Record Revenue in Fiscal 2025

Twist Bioscience Corporation, a mid-cap biotech company, specializes in synthetic DNA tools for various sectors including medicine and agriculture, leveraging its innovative silicon-based DNA synthesis platform. The company reported a record revenue of $376.6 million for fiscal 2025, marking a 20% increase from the previous year, with significant growth across its SynBio, NGS, and Biopharma segments. The fourth quarter alone saw a 17% revenue increase to $99 million, continuing its streak of sequential growth. Key financial metrics include an improved gross margin of 50.7% for the year and a reduced net loss of $77.7 million, down from $208.7 million in fiscal 2024. The company also made strategic advancements, including launching new products and expanding its customer base. Looking ahead, Twist Bioscience anticipates continued growth with projected revenues between $425 million and $435 million for fiscal 2026, while maintaining a gross margin above 52% and achieving adjusted EBITDA breakeven by the fourth quarter.